Common Contracts

Acquisition agreement for Iveric Bio

Acquisition Agreement • November 14th, 2024 • Delaware

• Contract Type
  Acquisition Agreement
• Filed
  November 14th, 2024
• Jurisdiction
  Delaware

Astellas Pharma and Iveric bio announced that on April 29, 2023 the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, a wholly-owned subsidiary of Astellas US Holding, has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion.